Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis

Chacko, Joseph A; Stout, Paul W; Archer, Robert L.; Baltz, Brad

doi:10.1016/j.msard.2021.102776

Cited by 6 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In reports on the adverse events of fingolimod, malignant lymphoma was reported in various organs, such as the bladder, eye, mediastinum, and skin [10][11][12][13]. Many of these cases were associated with EB virus infection and were worsened by fingolimod treatment.…”

Section: Discussionmentioning

confidence: 99%

A Case of Primary Central Nervous System Lymphoma That Developed in a Patient Receiving Fingolimod Therapy for Multiple Sclerosis

Takanashi,

Fukami,

Akimoto

et al. 2023

Cureus

View full text Add to dashboard Cite

Fingolimod is an oral medication for the prevention of multiple sclerosis relapse, and its efficacy has been demonstrated in several clinical trials. Fingolimod has various side effects, such as arrhythmia and hepatic dysfunction. In addition, there have been rare reports of the development of lymphoproliferative disorders in patients undergoing fingolimod therapy, including primary central nervous system lymphoma (PCNSL). We diagnosed and treated a multiple sclerosis patient who developed PCNSL while undergoing fingolimod therapy. Fourteen months after starting fingolimod therapy, the patient developed aphasia, and underwent biopsy analysis for a lesion displaying a homogeneous gadolinium-enhanced lesion in the left frontal lobe. The lesion was diagnosed as diffuse large B-cell lymphoma by pathological examination. After the diagnosis, the patient received chemotherapy together with methotrexate combination therapy, and the lesion became smaller and the patient’s symptoms improved. Although several autopsy cases of PCNSL in patients who received fingolimod therapy have been reported, there have been few reports to date of patients diagnosed by biopsy analysis.

show abstract

Section: Discussionmentioning

confidence: 99%